CD274 and glioblastoma: However, for glioblastoma, anti‐PD‐1/PD‐L1 immunotherapy has shown limited satisfactory results in clinical trials, revealing low tumor response and no prolongation of patient survival, which limits its therapeutic application in glioblastoma.4